![]() Once in academia, Roger exploited his experience with ICI to be an effective collaborator with industry, understanding industrial perspectives and tailoring his scientific approach to solve their problems. The wide range of industries he has worked with is reflected here in contributions on batteries, (8) agrochemicals, (9) optoelectronics, (10−12) foodstuffs, (13,14) and fuels. However, it was the pharmaceutical industry that was to benefit most. During the 1990s, this industry became more aware of the importance of crystal chemistry for intellectual property and pharmaceutical performance. Pharmaceutical companies responded by recruiting increasing numbers of crystallization scientists, many of whom came with Roger’s scientific approaches to crystallization, as well as the skills and conviction needed to convince skeptical colleagues to implement them. Through better ways to discover and develop new crystallization processes and crystalline forms, and to tackle solid-state challenges, our society continues to benefit from pharmaceuticals that perform robustly to exacting requirements. ![]() More than 20 crystallization scientists trained by Roger have gone on to work in the pharmaceutical industry for at least six different companies. This virtual special issue in Celebration of the Career of Roger Davey contains papers that deal with pharmaceutical materials (15−21) or arise from the collaboration between academia and the pharmaceutical industry (22−24) or come directly from the pharmaceutical industry. (25,26)Īfter 25 years of academic work at Manchester, 200+ scientific publications, an army of Ph.D. Students and PDRA fellows supervised, a countless number of collaborators, and a myriad of insightful contributions to the fields of crystallization and crystal engineering, Roger ( Figure 3) retired officially from the University of Manchester in 2020.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |